BLOOD PRESSURE IS ASSOCIATED WITH DIABETIC RETINOPATHY IN TYPE 1 BUT NOT IN TYPE 2 DIABETES

Tomislav Bulum1,2, Martina Tomić1, Romano Vrabec1, Miljenka Martinović Bošković6, Spomenka Ljubić1,2 and Ingrid Prkačin2,3

1Vuk Vrhovac Clinic for Diabetes, Endocrinology and Metabolic Diseases, University Hospital Merkur; 2Medical School, University of Zagreb, Zagreb, Croatia; 3Department of Internal Medicine, Merkur University Hospital, Zagreb, Croatia

SUMMARY – The aim of this study was to investigate the role of systolic blood pressure (SBP) and diastolic blood pressure (DBP) in the development of diabetic retinopathy (DR) in type 1 and type 2 diabetes and to determine the differences between these two types of diabetes. This cross-sectional study included 84 patients with type 1 diabetes (T1DM) and 107 patients with type 2 diabetes (T2DM). Ophthalmologic retinal examination included indirect slit-lamp fundoscopy, color fundus photography according to EURODIAB (EUROpe and DIABetes) protocol and optical coherence tomography. Blood pressure was measured with a mercury sphygmomanometer after a 10-minute rest period. In T1DM, DR was positively associated with SBP (p = 0.035), HbA1cmedian (p < 0.001) and hypertensive retinopathy (p < 0.001), while in T2DM DR was positively related only to HbA1cmedian (p = 0.021). Binary logistic regression analysis (no DR/DR) showed that diabetes duration and HbA1cmedian were the main predictors of DR in both types of diabetes. In contrast, SBP (OR = 1.05, p = 0.045) and hypertensive retinopathy (OR = 3.75, p < 0.001) were the main predictors/indicators of DR only in T1DM. In conclusion, blood pressure is associated with DR in type 1 but not in type 2 diabetes.

Keywords: blood pressure, type 1 and type 2 diabetes, retinopathy, risk factors

Introduction

The prevalence of diabetes mellitus is rapidly increasing and is now the most common non-communicable disease, globally projected to affect over 700 million people by 2045. The prevalence of diabetes mellitus is rapidly increasing and is now the most common non-communicable disease, globally projected to affect over 700 million people by 2045. The prevalence of diabetes mellitus is rapidly increasing and is now the most common non-communicable disease, globally projected to affect over 700 million people by 2045. The prevalence of diabetes mellitus is rapidly increasing and is now the most common non-communicable disease, globally projected to affect over 700 million people by 2045. The prevalence of diabetes mellitus is rapidly increasing and is now the most common non-communicable disease, globally projected to affect over 700 million people by 2045.

Diabetic retinopathy (DR), a microvascular complication of diabetes, is one of the leading causes of visual impairment and blindness in patients with type 1 (T1DM) and type 2 (T2DM) diabetes. T1DM is an autoimmune disease that result from autoimmune β-cell destruction with absolute insulin deficiency and accounts for 5-10% of diabetes, while T2DM occurs more frequently, comprising more than 90% of all diabetes cases. It is associated with insulin resistance and metabolic syndrome components (obesity, hypertension, and dyslipidemia). Prospective studies identified hyperglycemia, diabetes duration and blood pressure as the most important risk factors for development of DR in T1DM and T2DM. Besides diabetes duration, hyperglycemia and hypertension are modifiable risk factors.

In patients with diabetes, high blood pressure increases blood flow and hypothetically damages the retinal capillary endothelial cells. The results from the large and prospective United Kingdom Prospective Diabetes Study (UKPDS) showed that the incidence

Corresponding author: Assistant Professor Tomislav Bulum, MD, PhD, Vuk Vrhovac Clinic for Diabetes, Endocrinology and Metabolic Diseases, University Hospital Merkur, Medical School, University of Zagreb, Croatia, Dugi dol 4a E-mail: tomobulum@gmail.com
of DR was associated with systolic blood pressure (SBP) in T2DM. T2DM in the highest tertile range with SBP over 140 mmHg had almost a three times higher risk of development of DR compared to subjects in the lowest tertile range with SBP below <125 mmHg. In contrast, results from the 25-year follow-up of the WESDR (Wisconsin Epidemiologic Study of Diabetic Retinopathy) study, which included T1DM, found that diastolic blood pressure (DBP) was a significant predictor of the progression of DR. However, in the same study neither SBP nor DBP at baseline were associated with the incidence and progression of DR in T2DM. We previously observed that SBP is a risk factor for the development and progression of DR in T1DM, but in patients with normal renal function and normoalbuminuria. In contrast, we previously observed that DBP is a risk factor and predictor for cataract development in T2DM.

The aim of this study was to investigate the role of SBP and DBP in the development of DR in T1DM and T2DM.

Subjects, materials and methods

This cross-sectional study included 84 T1DM and 107 T2DM patients at the Department of Ophthalmology and the Department of Diabetes of the Vuk Vrhovac University Clinic for Diabetes, Endocrinology and Metabolic Diseases in Zagreb over a six-month period. The study was performed in accordance with the Helsinki Declaration and approved by the hospital’s ethics committee. The patients included in the study received both written and oral information about the study and signed a consent form. T1DM and T2DM were defined according to the ADA classification. We excluded from the study all illnesses that may affect eye function and blood pressure, such as therapy with corticosteroids or cytostatics, immunological and acute infectious inflammatory diseases, pregnant women and patients with other eye diseases. At the inclusion visit, consent forms were signed, blood samples were collected for laboratory analyses, and complete clinical and ophthalmologic retinal examinations were performed.

All subjects were examined the morning after an overnight fast to determine HbA1c, serum lipids and serum creatinine. Basic anthropometric measurements were performed on all study subjects, including body mass index (BMI). HbA1c was determined at the beginning of the study from a single venous blood sample. HbA1c was obtained by a statistical analysis of data from the National Registry for Diabetes (CroatDiabNet) and used as a marker of long-term glycemic control. The statistical analysis included HbA1c values from venous blood samples taken from each patient at 3-4-month intervals over the past three years. SBP and DBP were measured with an ambulatory mercury sphygmomanometer after a 10-min rest period, and a mean of three measurements was used.

The ophthalmologic retinal examination included indirect slit-lamp fundoscopy, color fundus photography, and optical coherence tomography (OCT) of the macula after mydriasis with eye drops containing 0.5% tropicamide. Color fundus photographs of two fields (macular field, disc/nasal field) of both eyes were taken with the standard 45° fundus camera (Visucam NM/FA, Carl Zeiss Meditec) according to the EU-RODIAB retinal photography methodology. Two medical retina specialists independently graded the photographs and assigned a DR level. The final diagnosis for each patient was determined from the level of DR of the worse eye using EURODIAB criteria. OCT of the macula of both eyes was performed by Spectral Domain OCT (SD-OCT Copernicus REVO NX, Optopol Technology), and diabetic macular edema (DME) was defined by the proposed international clinical DR and diabetic macular edema disease severity scales. Hypertensive retinopathy was defined and graded using the Keith-Wagener-Barker classification. Patients with active proliferative DR and active DME were not included in the study.

Statistical analysis was performed with the Statistics software package, version 14.0 (TIBCO Inc., USA). The normality of data distribution was evaluated by the Kolmogorov-Smirnov test and the homogeneity of variance by the Levene test. The results of the descriptive analyses were expressed as means ± SD or medians (min-max) for continuous variables and as numbers and percentages for categorical variables. Differences between continuous data were determined by t-test or a Mann-Whitney test. A nonparametric test was used when the assumption of homogeneity of variance for tested variables was not met. Differences among categorical data were evaluated by the Chi-square test. The Pearson’s and Spearman rank correlation tests were used. ANOVA with two main factors.
and their interaction was used to compare the analyzed variables according to the type of diabetes and the DR status. Binary logistic regression analysis was used to assess the strength and independence of the associations between DR and the risk factors. In all analyses, \( p < 0.05 \) was considered statistically significant.

**Results**

This study included 84 (48 male/36 female) T1DM and 107 (67 male/40 female) T2DM. Their basic characteristics and clinical parameters are presented in Table 1. T2DM were significantly older (\( p < 0.001 \)) and had significantly higher SBP (\( p < 0.001 \)), while T1DM had significantly higher \( \text{HbA}_1c \) (\( p = 0.038 \)). No significant differences in gender, diabetes duration, DBP, \( \text{HbA}_1c \), and number (percentage) of patients with diabetes and hypertensive retinopathy were found between the patients with different types of diabetes.

According to the DR status, patients were divided into two groups: Gr 1 (patients without DR; type 1 \( n=51 \), type 2 \( n=65 \)) and Gr 2 (patients with DR; type 1 \( n=33 \), type 2 \( n=42 \)). Table 2 presents the clinical parameters of T1DM and T2DM divided into two DR groups. T1DM with DR had significantly higher SBP than patients without DR (\( p = 0.035 \)), while no significant difference in SBP in T2DM with and without DR was observed (\( p = 0.062 \)). Also, the two DR groups in both types of diabetes did not significantly differ in DBP, and \( \text{HbA}_1c \) determined at the beginning of the study, but \( \text{HbA}_1c_{\text{median}} \) was significantly higher in patients with DR than those without DR in T1DM (\( p < 0.001 \)) and T2DM (\( p = 0.021 \)). T1DM with DR had significantly more frequent signs of hypertensive retinopathy than those test subjects without DR (\( p < 0.001 \)), although no significant difference in the number (percentage) of patients with and without DR and concomitant hypertensive retinopathy was found in T2DM (\( p = 0.079 \)) (Table 2, Figure 1). Figure 2 presents the macular field of the left and right eye of one T1DM with non-proliferative DR and concomitant hypertensive retinopathy Gr. 3/2.

In T1DM DR was positively associated with SBP (\( p = 0.035 \)), \( \text{HbA}_1c_{\text{median}} \) (\( p < 0.001 \)) and hypertensive retinopathy (\( p < 0.001 \)), while in T2DM it was positively related only to \( \text{HbA}_1c_{\text{median}} \) (\( p = 0.021 \)) (Table 3).

The differences in SBP and DBP according to the type of diabetes and DR status were evaluated by ANOVA with two main factors and their interaction (Table 4, Figure 3). The among-group differences in SBP were observed according to the type of diabetes (\( p < 0.001 \)) and DR status (\( p = 0.009 \), but no significant difference in SBP was found in the interaction between the type of diabetes and DR status (\( p = 0.378 \)). For DBP, no differences were observed among-group according to the type of diabetes (\( p = 0.451 \) and DR status (\( p = 0.904 \)) or in the interaction of the type of diabetes and DR status (\( p = 0.253 \)).

---

**Table 1. Basic characteristics and clinical parameters of type 1 and type 2 diabetic patients included in the study.**

|                        | T1DM (n=84) | T2DM (n=107) | \( t^a \) | \( \chi^b \) | \( Z^c \) | \( p \) |
|------------------------|-------------|--------------|-----------|-------------|---------|------|
| Age (years)*           | 41.54±7.58  | 66.74±8.01   | -14.976*  |             |         | <0.001|
| Gender (m/f)**         | 36/48       | 40/67        | 0.281b    | 0.596       |         |      |
| Diabetes duration (year)† | 15.5 (8-35) | 15 (7-25)    | 1.289b    | 0.159       |         |      |
| SBP (mmHg)*            | 123.75±21.15| 142.34±23.03 | -3.864a   | <0.001      |         |      |
| DBP (mmHg)*            | 78.39±11.39 | 81.07±12.53  | -1.026c   | 0.307       |         |      |
| \( \text{HbA}_1c \) (%)| 6.77±1.37   | 6.50±1.11    | 1.111a    | 0.268       |         |      |
| \( \text{HbA}_1c_{\text{median}} \) (%) | 7.25±1.11 | 6.80±0.84   | 2.124e    | 0.038       |         |      |
| Diabetic retinopathy** | 33 (39.3)   | 42 (39.2)    | 0.000b    | 0.997       |         |      |
| Hypertensive retinopathy** | 27 (32.1) | 40 (37.4)    | 0.264b    | 0.608       |         |      |

* mean ± SD ** number (percentage) † median (min-max) ' t-test b Chi-square test c Mann-Whitney test T1DM = type 1 diabetic patients; T2DM = type 2 diabetic patients; SBP = systolic blood pressure; DBP = diastolic blood pressure; \( \text{HbA}_1c \) = glycated hemoglobin value determined at the beginning of the study from a single venous blood sample; \( \text{HbA}_1c_{\text{median}} \) = glycated hemoglobin value obtained by statistical analysis of data from the National Registry for Diabetes (CroDiabNet).
Table 2. Clinical parameters of type 1 and type 2 diabetic patients divided into two groups according to the diabetic retinopathy status.

|                  | T1DM (n=84) | T2DM (n=107) |
|------------------|-------------|--------------|
|                  | DR          | t^a Chi^b    | p   | DR          | t^a Chi^b    | p   |
| SBP (mmHg)*      |             |              |     |             |              |     |
| Gr 1             | 117.06±18.12| -2.228^a     | 0.035 | Gr 1         | 139.00±22.97| -1.887^a     | 0.062 |
| Gr 2             | 134.09±22.12|              |     | Gr 2         | 147.50±22.42|              |     |
| DBP (mmHg)*      |             |              |     |             |              |     |
| Gr 1             | 77.06±12.75 | -0.765^a     | 0.451 | Gr 1         | 82.15±12.89 | 1.109^a      | 0.269 |
| Gr 2             | 80.45±9.07  |              |     | Gr 2         | 79.40±11.90 |              |     |
| HbA1c (%)*       |             |              |     |             |              |     |
| Gr 1             | 6.57±1.49   | -0.933^a     | 0.359 | Gr 1         | 6.42±1.06   | -0.939^a     | 0.349 |
| Gr 2             | 7.07±1.16   |              |     | Gr 2         | 6.62±1.18   |              |     |
| HbA1c median (%)* |          |              |     |             |              |     |
| Gr 1             | 6.57±0.93   | -4.384^a     | <0.001 | Gr 1        | 6.65±0.81   | -2.350^a     | 0.021 |
| Gr 2             | 8.03±0.73   |              |     | Gr 2        | 7.03±0.83   |              |     |
| Hypertensive retinopathy** | |          |     |             |              |     |
| Gr 1             | 0 (0)       | 20.498^b     | <0.001 | Gr 1        | 20 (30.8)   | 3.095^b      | 0.079 |
| Gr 2             | 27 (81.8)   |              |     | Gr 2        | 20 (46.6)   |              |     |

* mean ± SD ** number (percentage) ^ t-test * Chi-square test

T1DM = type 1 diabetic patients; T2DM = type 2 diabetic patients; DR = diabetic retinopathy; Gr 1 = patients without DR (type 1 n=51; type 2 n=65); Gr 2 = patients with DR (type 1 n=33; type 2 n=42); SBP = systolic blood pressure; DBP = diastolic blood pressure; HbA1c = glycated hemoglobin value determined at the beginning of the study from a single venous blood sample; HbA1c_median = glycated hemoglobin value obtained by statistical analysis of data from the National Registry for Diabetes (CroDiabNet).

Fig. 1. Proportion of type 1 and type 2 diabetic patients with and without diabetic retinopathy and concomitant hypertensive retinopathy.

Binary logistic regression analysis (no DR/DR) showed that diabetes duration and long-term poor glycemic control, presented by HbA1c_median, were the main predictors of DR in both types of diabetes (Table 5). In contrast, SBP (OR = 1.05, p = 0.045) and hypertensive retinopathy (OR = 3.75, p < 0.001) were the main predictors/indicators of DR only in T1DM. Using the same logistic regression analysis, no significant association between DR and other analyzed variables were observed.

Discussion

The results of our study showed that in T1DM DR is positively associated with SBP, HbA1c_median and hypertensive retinopathy, while in T2DM DR is posi-
T. Bulum et al. Blood pressure and diabetic retinopathy

18 Acta Clin Croat, Vol. 61, (Suppl. 1) 2022

tively related only to HbA1c_median. Binary logistic regression analysis (no DR/DR) showed that diabetes duration and HbA1c_median were the main predictors of DR in both types of diabetes (Table 5). In contrast, SBP (OR = 1.05, p = 0.045) and hypertensive retinopathy (OR = 3.75, p < 0.001) were the main predictors/indicators of DR only in T1DM. Using the same logistic regression analysis, no significant association between DR and other analyzed variables was observed. Elevated blood glucose is a well-established risk factor for macrovascular and microvascular complications in patients with diabetes. The large prospective DCCT (Diabetes Control and Complications Trial) that included T1DM, as well as a UKPDS trial that included T2DM, showed that tight glycemic control significantly reduces the risk of the development and progression of DR and blindness.18,19

SBP and DBP are additional important modifiable risk factors for DR that have been documented in many trials. The ABCD (Appropriate Blood Pressure Control in diabetes) and UKPDS are large, prospective trials that included T2DM and observed that strict blood pressure control can prevent and/or limit DR and visual dysfunction.20,21 In ABCD study there were no significant differences in SBP and DBP between DR groups in T2DM. Similar to our results, blood pressure was similar in normotensive normoalbuminuric T2DM patients with and without DR22.

Table 3. Correlation between diabetic retinopathy and clinical parameters in type 1 and type 2 diabetic patients included in the study.

|                  | Diabetic retinopathy | T1DM | T2DM |
|------------------|----------------------|------|------|
|                  | r²       | t     | p    | r²       | t     | p    |
| SBP              | 0.160    | 2.228 | 0.035| 0.033    | 1.887 | 0.062|
| DBP              | 0.022    | 0.765 | 0.451| 0.012    | -1.109| 0.269|
| HbA₁c            | 0.032    | 0.933 | 0.359| 0.008    | 0.939 | 0.349|
| HbA₁c_median     | 0.425    | 4.384 |<0.001| 0.049    | 2.350 | 0.021|
| Hypertensive retinopathy | Spearman R | t(N-2) | p     | Spearman R | t(N-2) | p     |
|                  | 0.856    | 8.428 |<0.001| 0.170    | 1.768 | 0.079|

T1DM = type 1 diabetic patients; T2DM = type 2 diabetic patients; SBP = systolic blood pressure; DBP = diastolic blood pressure; HbA₁c = glycated hemoglobin value determined at the beginning of the study from a single venous blood sample; HbA₁c_median = glycated hemoglobin value obtained by statistical analysis of data from the National Registry for Diabetes (CroDiabNet).

Fig. 2. Macular field of right (a) and left (b) eye of type 1 diabetic patient with nonproliferative diabetic retinopathy and concomitant hypertensive retinopathy Gr 3/2.
High blood pressure in T1DM has been shown to significantly increase the risk of proliferative DR in the Wisconsin Epidemiology Study.\textsuperscript{23} Another study that also included T1DM indicated that each increment of 5 mmHg in night-time SBP and DBP increase the risk of DR up to 40\% even in T1DM without hypertension.\textsuperscript{24} In contrast, it has been documented that normoalbuminuric T1DM with hypertension had no higher prevalence of DR compared to normoalbuminuric normotensive patients.\textsuperscript{25} Another study that in-

---

**Table 4. Results of two-way ANOVA for the differences in systolic and diastolic blood pressure according to the type of diabetes, diabetic retinopathy status, and their interaction.**

|                          | SBP         | DBP         |
|--------------------------|-------------|-------------|
|                          | df  | F      | p    | F      | p    |
| DM type                  | 1   | 13.431 | <0.001 | 0.571 | 0.451 |
| DR                       | 2   | 7.006  | 0.009  | 0.015 | 0.904 |
| DM type & DR             | 3   | 0.782  | 0.378  | 1.317 | 0.253 |

DM type = type of diabetes mellitus; DR = diabetic retinopathy status; SBP = systolic blood pressure; DBP = diastolic blood pressure.

---

**Table 5. Predictors and indicators of diabetic retinopathy in type 1 and type 2 diabetes using binary logistic regression analysis.**

|                          | T1DM                   | T2DM                   |
|--------------------------|------------------------|------------------------|
|                          | OR (95\% CI) | p        | OR (95\% CI) | p        |
| Diabetes duration        | 1.20 (1.05-1.38) | 0.005   | 1.17 (1.08-1.27) | <0.001  |
| SBP                      | 1.05 (0.99-1.10) | 0.045   | 1.02 (0.99-1.04) | 0.065   |
| DBP                      | 1.03 (0.95-1.10) | 0.438   | 0.98 (0.95-1.01) | 0.269   |
| HbA$_1$c                 | 1.32 (0.72-2.41) | 0.351   | 1.18 (0.83-1.68) | 0.348   |
| HbA$_1$c$_{median}$      | 6.92 (1.58-30.17) | 0.007   | 1.75 (1.07-2.87) | 0.024   |
| Hypertensive retinopathy | 3.75 (1.78-7.89) | <0.001  | 2.05 (0.91-4.61) | 0.081   |

T1DM = type 1 diabetes mellitus; T2DM = type 2 diabetes mellitus; SBP = systolic blood pressure; DBP = diastolic blood pressure; HbA$_1$c = glycated hemoglobin value determined at the beginning of the study from a single venous blood sample; HbA$_1$c$_{median}$ = glycated hemoglobin value obtained by statistical analysis of data from the National Registry for Diabetes (CraDiabNet).
cluded normoalbuminuric T1DM found higher only night blood pressure in patients with DR compared to those without retinopathy. The results from the EURODIAB Prospective Complications Study, which included T1DM, found that DBP is a significant risk factor for DR after adjusting for nephropathy, while nighttime 24-hour ambulatory SBP was associated with the presence and severity of DR in T1DM without nephropathy and hypertension. In our study, only SBP was associated with DR, which is in line with our previous study in which we observed that SBP is a risk factor for the development and progression of DR in T1DM with normal renal function and normoalbuminuria, and with the prospective UKPDS study, which also found higher relative risk for the incidence of DR with higher SBP in T2DM. However, the methods used for diagnosis of blood pressure in our study (single standard sphygmomanometer not 24-hour ambulatory blood pressure) may influence the final results of our investigation and make a comparison between studies difficult.

In T1DM treatment with the ACE-inhibitor lisinopril resulted in a statistically significant 50% reduction in the progression of DR and an 82% reduction in the progression to proliferative DR even after an adjustment for glycemic control. In the Diabetes Remission Clinical Trial (DIRECT) 5 years of ACE-inhibitor candesartan treatment in T1DM reduced the incidence of DR in severity by 18% and reduced the incidence of DR progression by 35%. ACE-inhibitors have a beneficial hemodynamic effect, reduce endothelial dysfunction via enhancement of nitric oxide and blocking vascular endothelial growth factor receptors, and improve the blood-retinal barrier. The beneficial effect on DR is observed even in T1DM with blood pressure in the “normal range,” which is also observed in UKPDS, where researchers reported that there was no evidence of a threshold effect of SBP for the incidence of microvascular complications in T2DM. It should be stressed that the majority of our T1DM were not on antihypertensive therapy and that the mean SBP and DBP was within the normal range for patients with diabetes (mean blood pressure 123/78 mmHg).

In diabetic mouse models, hypertension significantly increases the thickness of the basement membrane and permeability to albumin. The frequency of acellular capillaries, the morphological gold-standard marker for DR, is doubled in diabetic rats with hypertension compared to those without hypertension. Deposions of advanced glycation end products-proteins in the retinal vasculature activated with hypertension induced development of DR in that study. Other studies also suggested that hypertension could induce oxidative stress and inflammation, risk factors strongly implicated in the pathogenesis of DR, and contributed to the development of DR. In animal models with diabetes and genetic susceptibility to hypertension, inflammation processes in the retina are present before the establishment of full hypertension. It seems that the coincidence of hyperglycemia and hypertension can accelerate inflammation and oxidative stress, which are pathological processes involved in DR development and progression.

The present study has a number of potential limitations. First, its design was cross-sectional and sample size in subgroups was small, which limited our ability to infer a causal relation between DR and blood pressure. Second, ambulatory blood pressure measurement is more useful than causal or office blood pressure measurement, and the methods used for diagnosis of DR and blood pressure may have an influence on the final results, making comparisons of the findings between studies difficult. Third, our analyses were based on a single measurement of blood pressure that may not reflect the relation over time. Fourth, this cohort had little racial/ethnic diversity and our data would be primarily relevant to a white European population.

In conclusion, our results suggest that diabetes duration and HbA1c are the main predictors of DR in both types of diabetes. However, SBP and hypertensive retinopathy were the predictors/indicators of DR only in T1DM, indicating that blood pressure is associated with tDR in Type 1 but not in type 2 diabetes. This points to the need for close monitoring of blood pressure in T1DM aimed at preventing or limiting the progression of DR.

Declaration of Competing Interest

The authors declare that they have no known competing financial interests or personal relationships that could have influenced the work reported in this paper.

The authors state that this manuscript has not been published previously and is not currently being assessed for publication by any journal other than the Acta Clinica Croatica. The authors did not receive any
financial support for the study. No proprietary interest is involved in the study.

Acknowledgments

This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

References

1. International Diabetes Federation (IDF). IDF Diabetes Atlas 9th edition. Belgium: International Diabetes Federation 2019. Available at: http://www.diabetesatlas.org/
2. van Hecke MV, Dekker JM, Stehouwer CD, Polak BC, Fuller JH, Sjolie AK, et al. Diabetic retinopathy is associated with mortality and cardiovascular disease incidence: EURODIAB Prospective Complications Study. Diabetes Care. 2005;28(6):1383-9. doi: 10.2337/diacare.28.6.1383.
3. American Diabetes Association. Classification and diagnosis of diabetes. Diabetes Care. 2021;44(suppl. 1):S15-S33. doi: 10.2337/dc21-0002.
4. Downie E, Craig ME, Hing S, Cusumano J, Chan AK, Donaghue KC. Continued reduction in the prevalence of retinopathy in adolescents with type 1 diabetes: role of insulin therapy and glycomic control. Diabetes Care. 2011;34(11):2368-73. doi: 10.2337/dc11-0102.
5. Yau JW, Rogers SL, Kawasaki R, Lamoureux EL, Kowalski JW, Bek T. Global prevalence and major risk factors of diabetic retinopathy. Diabetes Care. 2012;35(3):556-64. doi: 10.2337/dc11-1909.
6. Klein R, Moss SE, Zinman B, Gardiner R, Suissa S, et al. The relation of ambulatory blood pressure and pulse rate to retinopathy in type 1 diabetes mellitus. the renin-angiotensin system study. Ophthalmology. 2006;113(12):2231-6. doi: 10.1016/j.opth.2006.06.003.
7. Klein R, Klein BEK. Blood pressure control and diabetic retinopathy. Br J Ophthalmol. 2002;86(4):365-7. doi: 10.1136/bjo.86.4.365.
8. Shaya FT, Aljawadi M. Diabetic retinopathy. Clin Ophthalmol. 2007;1(3):259-65.
9. Kohner EM. Diabetic retinopathy. Br Med Bull. 1989;45(1):148-73.
10. Stratton IM, Kohner EM, Aldington SJ, Turner RC, Holman RR, Manley SE, et al. UKPDS 50: risk factors for incidence and progression of retinopathy in type II diabetes over 6 years from diagnosis. Diabetologia. 2001;44(2):156–63. doi: 10.1007/s001250051594.
11. Klein R, Klein BEK, Moss SE, Cruickshanks KJ. The Wisconsin Epidemiologic Study of Diabetic Retinopathy. XVII. The 14-year incidence and progression of diabetic retinopathy and associated risk factors in type 1 diabetes. Ophthalmology. 1998;105(10):1801-15. doi: 10.1016/S0161-6420(98)91020-X.
12. Klein R, Klein BEK, Moss SE, Davis MD, DeMets DL. Is blood pressure a predictor of the incidence or progression of diabetic retinopathy? Arch Intern Med. 1989;149(11):2427-32.
13. Bulum T, Blaslov K, Dovnjak L. Risk factors for development and progression of nonproliferative retinopathy in normoalbuminuric patients with type 1 diabetes. Diabetes Res Clin Pract. 2014;106(3):555-9. doi: 10.1016/j.diabres.2014.09.018.
14. Tomici M, Vrabec R, Ljubicic S, Bulum T, Prkačin I, Rahelić D. Renal function is associated with cataract development in patients with type 2 diabetes. Acta Clin Croat. (Suppl. 1) 2021;60:18-23. doi: 10.20471/acc.2021.60.s1.03.
15. Aldington SJ, Kohner EM, Meuer S, Klein R, Sjolie AK. Methodology for retinal photography and assessment of diabetic retinopathy: the EURODIAB IDDM Complications Study. Diabetologica. 1995;38(4):437-44.
16. Wilkinson CP, Ferris FL 3rd, Klein RE, Lee PP, Agardh CD, Davis M, et al. Global Diabetic Retinopathy Project Group. Proposed international clinical diabetic retinopathy and diabetic macular edema disease severity scales. Ophthalmology 2003;110(9):1677-82. doi: 10.1016/S0161-6420(03)00475-5.
17. Modi P, Arisiwalla T. Hypertensive Retinopathy. [Updated 2021 Jul 10]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2022 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK525980/.
18. Diabetes Control and Complications Trial (DCCT) research group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993;329(14):977-86. doi: 10.1056/NEJM199309303291401. Effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993;329(14):977-86. doi: 10.1056/NEJM199309303291401.
19. United Kingdom Prospective Diabetes Study (UKPDS) group. Intensive blood glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998;352(9131):837-53.
20. Matthews DR, Stratton IM, Aldington SJ, Holman RR, Kohner EM, UK Prospective Diabetes Study Group. Risks of progression of retinopathy and vision loss related to tight blood pressure control in type 2 diabetes mellitus (UKPDS 69). Arch Ophthalmol. 2004;122(11):1631-40. doi: 10.1001/archopht.122.11.1631.
21. Schirer RW, Estacio RO, Meherl PS, Hiattet WR. Appropriate blood pressure control in hypertensive and normotensive type 2 diabetes mellitus: a summary of the ABCD trial. Nat Clin Pract Nephrol. 2007;3(8):428-38. doi: 10.1038/ncpneckph0559.
22. Imano E, Miyatsuka T, Motomura M, Kanda T, Matsuhisa M, Kajimoto Y, et al. Heart rate elevation and diabetic retinopathy in patients with type 2 diabetes mellitus and normoalbuminuria. Diabetes Res Clin Pract. 2001;52(3):185-91. doi: 10.1016/s0168-8227(01)00219-4.
23. Klein R, Knudston MD, Lee KE, Gangnon R, Klein BE. The Wisconsin Epidemiologic Study of Diabetic Retinopathy: XXII the twenty-five-year progression of retinopathy in persons with type 1 diabetes. Ophthalmology. 2008;115(11):1859-68. doi: 10.1016/j.jophtha.2008.08.023.
24. Rodrigues TC, Canani LH, Viatroski RS, Hoffmann LH, Esteves JF, Gross JL. Masked hypertension, nocturnal blood pressure and retinopathy in normotensive patients with type 1 diabetes. Diabetes Res Clin Pract. 2010;87(2):240–5. doi: 10.1016/j.diabres.2009.10.016.

25. Norgaard K, Feldt Rasmussen B, Deckert T. Is hypertension a major independent risk factor for retinopathy in type 1 diabetes? Diabet Med. 1991;8(4):334-7. doi: 10.1111/j.1464-5491.1991.tb01606.x.

26. Poulsen PL, Bek T, Ebbehøj E, Hansen KW, Mogensen CE. 24-h ambulatory blood pressure and retinopathy in normoalbuminuric IDDM patients. Diabetologia. 1998;41(1):105-10. doi: 10.1007/s001250050874.

27. Sjolie AK, Stephenson JM, Aldington S, Kohner E, Janka H, Stevens L, et al. Retinopathy and vision loss in insulin-dependent diabetes. The EURODIAB IDDM complications study. Ophthalmology. 1997;104(2):252-260. doi: 10.1016/s0161-6420(97)00327-3.

28. Adler AI, Stratton IM, Neil HA, Yudkin JS, Matthews DR, Cull CA, et al. Association of systolic blood pressure with macrovascular and microvascular complications in type 2 diabetes (UKPDS 36): Prospective observational study. BMJ. 2000;321(7258):412-9. doi: 10.1136/bmj.321.7258.412.

29. Chaturvedi N, Sjolie AK, Stephenson JM, Abrahamian H, Keipes M, Castellarin A, et al. Effect of lisinopril on progression of retinopathy in normoalbuminuric people with type 1 diabetes. The EUCLID Study Group. EURODIAB Controlled Trial of Lisinopril in Insulin-Dependent Diabetes Mellitus. Lancet. 1998;351(9095):28–31. doi: 10.1016/s0140-6736(97)06209-0.

30. Wright AD, Dodson PM. Diabetic retinopathy and blockade of the renin-angiotensin system: new data from the DIRECT study program. Eye (Lond). 2010;24(1):1-6. doi: 10.1038/eye.2009.189.

31. Deinum J, Chaturvedi N. The renin-angiotensin system and vascular disease in diabetes. Semin Vasc Med. 2002;2(2):149-56. doi: 10.1055/s-2002-32038.

32. Dosso AA, Leuenberger PM, Rungger-Brandl E. Remodeling of retinal capillaries in the diabetic hypertensive rat. Invest Ophthalmol Vis Sci. 1999;40(10):2405–10.

33. Hammes HP, Brownlee M, Edelstein D, Saleck M, Martin S, Federlin K. Aminoguanidine inhibits the development of accelerated diabetic retinopathy in the spontaneous hypertensive rat. Diabetologia. 1994;37(1):32-5. doi: 10.1007/BF00428774.

34. Vaziri ND, Rodriguez-Iiturbe B. Mechanisms of disease: oxidative stress and inflammation in the pathogenesis of hypertension. Nat Clin Pract Nephrol. 2006;2(10):582–93. doi: 10.1038/ncpneph0283.

35. Silva KC, Pinto CC, Biswas SK, de Faria JB, de Faria JM. Hypertension increases retinal inflammation in experimental diabetes: A possible mechanism for aggravation of diabetic retinopathy by hypertension. Curr Eye Res. 2007;32(6):533–41. doi: 10.1080/02713680701435391.

36. Mancia G, Parati G. Ambulatory blood pressure monitoring and organ damage. Hypertension. 2000;36(5):894–900. doi: 10.1161/01.hyp.36.5.894.

Sažetak

**KRVNI TLAK JE POVEZAN S DIJABETIČKOM RETINOPATIJOM KOD BOLENSKA SA TIPOM 1 ALI NE I KOD TIPOA 2 ŠEĆERNE BOLESTI**

**T. Bulum, M. Tomić, R. Vrabec, M. Martinović Bošković, S. Ljubići i I. Prkačin**

Cilj ovog istraživanja bio je istražiti povezanost sistoličkog krvnog tlaka (SK t) i dijabetičke retinopatije (DR) kod šećerne bolesti tipa 1 i tipa 2 te utvrditi razlike između ova dva tipa šećerne bolesti. Ova presječna studija uključila je 84 bolesnika sa šećernom bolešću tipa 1 (ŠB1) i 107 bolesnika sa šećernom bolešću tipa 2 (ŠB2). Oftalmološki pregled uključivao je neizravnu fundoskopiju, fotografiju fundusa u boji prema eur OkiAB (eur Ope and diABetes) protokolu i optičku koherentnu tomografiju. Krvni tlak izmjeren je živinim tlakomjerom nakon 10-minutnog mirovanja. Kod ŠB1 DR je bila pozitivno povezana sa SK t (p = 0,035), HbA1c medijan (p < 0,001) i hipertenzivnom retinopatijom (p < 0,001), dok je u ŠB2 DR bila pozitivno povezana samo s HbA1c medijan (p = 0,021). Analiza binarne logističke regresije (bez i sa DR) pokazala je da su trajanje šećerne bolesti i HbA1c medijan glavni prediktori DR u oba tipa šećerne bolesti. Međutim, SK t (OR = 1,05, p = 0,045) i hipertenzivna retinopatija (OR = 3,75, p < 0,001) bili su glavni prediktori/indi-katori DR samo u ŠB1. Zaključno, krvni tlak je povezan s DR kod tipa 1, ali ne i kod tipa 2 šećerne bolesti.

**Ključne riječi:** sistolički krvni tlak, šećerna bolest tip 1 i tip 2, retinopatija, čimbenici rizika